Brigatinib FoundationOne companion diagnostic - Foundation Medicine/Takeda
Alternative Names: Brigatinib FoundationOne® CDx - Foundation Medicine/Takeda; Brigatinib FoundationOne®Liquid CDxLatest Information Update: 15 Jul 2021
At a glance
- Originator Foundation Medicine
- Developer Foundation Medicine; Takeda Pharmaceuticals USA
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Non-small cell lung cancer
Most Recent Events
- 01 Jul 2021 Registered for Non-small cell lung cancer (Diagnosis) in USA
- 30 Jun 2021 Preregistration for Non-small cell lung cancer (Diagnosis) in USA before June 2021
- 21 Sep 2020 Foundation Medicine and Takeda Pharmaceuticals agree to develop brigatinib FoundationOne companion diagnostic for Non-small cell lung cancer